Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Drugs and Medicinal Substances

Temozolomide

Antineoplastic and Immunomodulating Agents

Temozolomide is an anticancer medication used to treat brain tumors including glioblastoma and anaplastic astrocytoma. It works as an alkylating agent, damaging tumor cell DNA by methylating guanine residues, which stops the cancer cells from dividing. The drug was approved in the European Union in January 1999 and in the United States in August 1999, and is usually taken orally or given intravenously in five day cycles followed by twenty three days of rest. Common side effects include nausea, hair loss, fatigue, and reduced blood cell counts.

Facts
Drug Class
Alkylating agent anticancer medication 1
Mechanism of Action
Alkylates and methylates DNA at guanine N-7 and O-6 positions, killing tumor cells 1
Approved Use
Treats newly diagnosed glioblastoma with radiotherapy then as monotherapy, and anaplastic astrocytoma 1
First Approved / Isolated Year
1999 1
Significant Risk
Risk of myelosuppression, increased when combined with other myelosuppressants 1
Classification
Approval Status
Approved 1
ATC ClassSourced to the subject's own account
L: Antineoplastic and Immunomodulating Agents 2
Route of Administration
Intravenous 3
Connections

Long-Form Articles

Sources
1. Temozolomide (Wikipedia)
  • Pharmacology section
    Temozolomide is an alkylating agent used to treat serious brain cancers
  • Mechanism of action section
    The therapeutic benefit of temozolomide depends on its ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine residues.
  • Medical uses section
    In the United States, temozolomide is indicated for the treatment of adults with newly diagnosed glioblastoma concomitantly with radiotherapy and subsequently as monotherapy treatment
  • History section
    It was approved for medical use in the European Union in January 1999, and in the United States in August 1999.
  • Interactions section
    Combining temozolomide with other myelosuppressants may increase the risk of myelosuppression.
  • https://en.wikipedia.org/wiki/Temozolomide, lead section
    oma and anaplastic astrocytoma. It is taken by mouth or via intravenous infusion.
  • Regulatory approval status
View the Source
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code L
Quote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
View the Source
3. Wikipedia
Wikipedia contributors, Wikimedia Foundation
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.